for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

China Resources Pharmaceutical Group Ltd

3320.HK

Latest Trade

7.45HKD

Change

0.03(+0.40%)

Volume

1,766,000

Today's Range

7.36

 - 

7.50

52 Week Range

7.06

 - 

12.70

As of on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
7.42
Open
7.36
Volume
1,766,000
3M AVG Volume
60.67
Today's High
7.50
Today's Low
7.36
52 Week High
12.70
52 Week Low
7.06
Shares Out (MIL)
6,284.51
Market Cap (MIL)
46,631.04
Forward P/E
9.54
Dividend (Yield %)
1.75

Next Event

Full Year 2019 China Resources Pharmaceutical Group Ltd Earnings Release

Latest Developments

More

China Resources Pharmaceutical Group Posts HY Profit Attributable HK$3,035.4 Million

China Resources Pharmaceutical Group Says Unit Acquired Shares In Zhejiang Interest'l Group

China Resources Pharmaceutical Group Says Li Guohui Resigns As CFO

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About China Resources Pharmaceutical Group Ltd

CHINA RESOURCES PHARMACEUTICAL GROUP LIMITED is a Hongkong-based investment holding company. The Company, along with its subsidiaries, is principally engaged in the research and development, manufacturing, distribution and retail of pharmaceutical and other healthcare products. The Company mainly operates through three segments. Pharmaceutical Manufacturing segment is engaged in the research and development, manufacturing and sale of pharmaceutical and other healthcare products. Pharmaceutical Distribution segment is engaged in the provision of distribution solutions to pharmaceutical manufacturers and dispensers, such as hospitals and other medical institutions, distributors and retail pharmacies. Pharmaceutical Retail segment is involved in the operation of retail pharmacies in China and Hongkong.

Industry

Biotechnology & Drugs

Contact Info

Room 4104-05, 41F,China Resources Buldng

No. 26, Harbour Road, Wan Chai

+852.null.25938991

http://www.crpharm.com/

Executive Leadership

Chuncheng Wang

Executive Chairman of the Board, Chief Executive Officer, Director

Jingwen Weng

Chief Financial Officer, Vice President, Executive Director

Yi Feng

Chairman of CR Double-Crane

Yufeng Qin

President of Dong-E-E-Jiao

Hong Chen

Senior Vice President

Key Stats

1.92 mean rating - 12 analysts
Sell
Hold
Buy
Revenue (MM, HKD)

2016

156.7K

2017

172.5K

2018

189.7K

2019(E)

207.0K
EPS (HKD)

2016

0.570

2017

0.550

2018

0.640

2019(E)

0.778
Price To Earnings (TTM)
9.67
Price To Sales (TTM)
0.24
Price To Book (MRQ)
1.13
Price To Cash Flow (TTM)
4.61
Total Debt To Equity (MRQ)
149.94
LT Debt To Equity (MRQ)
31.23
Return on Investment (TTM)
15.52
Return on Equity (TTM)
4.49

Latest News

Latest News

BRIEF-China Resources Pharmaceutical Group's units enter agreement to establish fund

* Units of co enter agreement with other partners in relation to establishment of fund of RMB2,500 million

BRIEF-China Resources Pharmaceutical says 9-mnth net profit RMB970.2 mln ​

* 9-month net profit RMB970.2 million versus RMB878.2 million a year ago

BRIEF-China Resources Pharmaceutical updates on formation of fund

* Unit under discussion with CR Capital GP, CR Capital LP, CR Sanjiu and CR Double-Crane

BRIEF-China Resources Pharmaceutical Group says HY profit attributable to owners of co HK$1.81 bln

* Hy profit for period attributable to owners of co hk$1.81 billion versus hk$1.64 billion a year ago

BRIEF-China Resources Pharma announces cooperation agreements

* Entered into cr bank strategic cooperation agreement 2017 and cr trust strategic cooperation agreement 2017 with cr bank and cr trust Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up